Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Sarcoma

Presenters

Milea Timbergen

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

M.J. Timbergen1, W.T. van der Graaf2, D.J. Grünhagen3, E. Younger4, S. Sleijfer5, A. Dunlop4, L. Dean6, C. Verhoef3, L.V. van de Poll-Franse7, O. Husson8

Author affiliations

  • 1 Surgical Oncology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 2 Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 3 Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam/NL
  • 4 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 5 Medical Oncology, Erasmus MC Cancer Institute, Rotterdam/NL
  • 6 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 7 Department Of Psychosocial Studies And Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 8 Department Of Psychosocial Studies And Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2640

Background

Desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft tissue tumour, which by local growth can significantly impact health related quality of life (HRQL). We aimed to identify the most important HRQL-issues of DTF patients.

Methods

DTF patients and health care professionals (HCPs) from the Netherlands and the United Kingdom individually ranked 124 issues according to their relevance. Patients also completed the European Organisation for Research and Treatment of Cancer QLQ-C30 core questionnaire (EORTC QLQ-C30). Outcomes of both groups were used to identify the most important HRQL-issues.

Results

The most highly ranked issues by patients (n = 29) were issues concerning ‘tumour growth’, ‘feeling that there is something in the body that does not belong there’, and ‘fear of tumour growth into adjacent tissues or organs’ with mean scores of 3.0, 2.9 and 2.8 respectively out of a total of 4 points. British patients scored higher on most issues compared to Dutch patients. Similarly, all HCPs (n = 31) gave higher scores on most issues compared to patients (total mean score of 2.3 versus a total mean of 1.9 for patients). The EORTC QLQ-C30 sum of scores was relatively high with a mean score of 77 points out of 100.

Conclusions

Patients affected by DTF experience psychological issues regarding the unpredictable tumour growth behaviour. Validation in a large international cohort is needed to devise a HRQL-questionnaire specific to DTF patients to fully address their needs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Stichting Coolsingel Rotterdam.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.